Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
暂无分享,去创建一个
Suzanne F. Jones | J. Bendell | H. Burris | J. Infante | S. Ikeda | M. Rothenberg | W. Zamboni | V. Keedy | Wooin Lee | Huali Wu | H. Kodaira | B. Zamboni | Whitney P. Kirschbrown | E. Chan